Literature DB >> 14709950

Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.

Amin Rostami-Hodjegan1, Ajmal M Amin, Edgar P Spencer, Martin S Lennard, Geoffrey T Tucker, Robert J Flanagan.   

Abstract

The measurement of plasma clozapine concentrations is useful in assessing compliance, optimizing therapy, and minimizing toxicity. We measured plasma clozapine and norclozapine (N-desmethylclozapine) concentrations in samples from 3782 patients (2648 male, 1127 female). No clozapine was detected in 291 samples (227 patients, median prescribed dose 300 mg/d). In 4963 (50.2 %) samples (2222 patients); plasma clozapine concentration ranged from 10 to 350 ng/mL.Step-wise backward multiple regression analysis (37 % of the total samples) of log10 plasma clozapine concentration against log10 clozapine dose (mg/d), age (year), sex (male = 0, female = 1), cigarette smoking habit (nonsmokers = 0; smokers = 1), body weight (kg), and plasma clozapine/norclozapine ratio (clozapine metabolic ratio, MR) showed that these covariates explained 48% of the observed variation in plasma clozapine concentration (C = ng/mL x 10-3) (P < 0.001) according to the following equation: log 10 (C) = 0.811 log 10 (dose) + 0.332 (MR) + 69.42 X 10 (-3) (sex) + 2.263 x 10 (-3) (age) + 1.976 x 10(-3) (weight) - 0.171 (smoking habit) - 3.180. This model and its associated confidence intervals were used to develop nomograms of plasma clozapine concentration versus dose for male and female smokers and nonsmokers. Predicted plasma clozapine changes by +48% in nonsmokers, +17% in females, +/-8 % for every 0.1 change in MR (reference 1.32), +/-4% for every 5 years (reference 40 years), and +/-5 % for every 10 kg body weight (reference 80 kg). The nomograms can be used (i) to individualize dosage to achieve a given target plasma clozapine concentration, and (ii) for quantitative evaluation of adherence by estimating the likelihood of an observed concentration being achieved by a given dosage regimen. The model has been validated against published data.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709950     DOI: 10.1097/01.jcp.0000106221.36344.4d

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  55 in total

1.  Comparability of whole-blood and plasma clozapine and norclozapine concentrations.

Authors:  R J Flanagan; B Yusufi; T R E Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

2.  Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Authors:  David R Plowchalk; Karen Rowland Yeo
Journal:  Eur J Clin Pharmacol       Date:  2012-01-19       Impact factor: 2.953

3.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 4.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

5.  Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.

Authors:  H P Sigurdsson; G Hefner; N Ben-Omar; A Köstlbacher; K Wenzel-Seifert; C Hiemke; E Haen
Journal:  J Neural Transm (Vienna)       Date:  2014-09-26       Impact factor: 3.575

Review 6.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  Adverse effects of clozapine in older patients: epidemiology, prevention and management.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

8.  Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine.

Authors:  Julia Korell; Bruce Green; Allan Rae; Bart Remmerie; An Vermeulen
Journal:  Eur J Clin Pharmacol       Date:  2018-02-01       Impact factor: 2.953

Review 9.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

10.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.